News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
739,248 Results
Type
Article (59432)
Company Profile (266)
Press Release (679532)
Multimedia
Podcasts (176)
Webinars (26)
Section
Business (204528)
Career Advice (3009)
Deals (34867)
Drug Delivery (147)
Drug Development (82427)
Employer Resources (176)
FDA (17311)
Job Trends (15310)
News (348879)
Policy (34834)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2769)
Academic (2)
Accelerated approval (36)
Adcomms (36)
Allergies (152)
Alliances (50854)
ALS (180)
Alzheimer's disease (1785)
Antibody-drug conjugate (ADC) (346)
Approvals (17496)
Artificial intelligence (588)
Autoimmune disease (174)
Automation (39)
Bankruptcy (365)
Best Places to Work (11571)
BIOSECURE Act (23)
Biosimilars (204)
Biotechnology (184)
Bladder cancer (163)
Brain cancer (61)
Breast cancer (661)
Cancer (5031)
Cardiovascular disease (441)
Career advice (2548)
Career pathing (42)
CAR-T (305)
CDC (59)
Celiac Disease (1)
Cell therapy (825)
Cervical cancer (37)
Clinical research (70022)
Collaboration (1841)
Company closure (5)
Compensation (1186)
Complete response letters (75)
COVID-19 (2915)
CRISPR (100)
C-suite (897)
Cystic fibrosis (152)
Data (6310)
Decentralized trials (2)
Denatured (56)
Depression (149)
Diabetes (523)
Diagnostics (6753)
Digital health (49)
Diversity (10)
Diversity, equity & inclusion (45)
Drug discovery (289)
Drug pricing (224)
Drug shortages (34)
Duchenne muscular dystrophy (245)
Earnings (87652)
Editorial (67)
Employer branding (22)
Employer resources (156)
Events (122274)
Executive appointments (1021)
FDA (20516)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1533)
Gene editing (217)
Generative AI (59)
Gene therapy (682)
GLP-1 (1123)
Government (4873)
Grass and pollen (8)
Guidances (387)
Healthcare (18854)
HIV (64)
Huntington's disease (50)
IgA nephropathy (87)
Immunology and inflammation (300)
Immuno-oncology (66)
Indications (109)
Infectious disease (3209)
Inflammatory bowel disease (203)
Inflation Reduction Act (16)
Influenza (125)
Intellectual property (253)
Interviews (560)
IPO (16570)
IRA (59)
Job creations (4093)
Job search strategy (2100)
JPM (70)
Kidney cancer (17)
Labor market (87)
Layoffs (643)
Leadership (41)
Legal (8590)
Liver cancer (96)
Longevity (15)
Lung cancer (677)
Lymphoma (385)
Machine learning (43)
Management (58)
Manufacturing (845)
MASH (176)
Medical device (13717)
Medtech (13769)
Mergers & acquisitions (19379)
Metabolic disorders (1403)
Multiple sclerosis (167)
NASH (22)
Neurodegenerative disease (353)
Neuropsychiatric disorders (102)
Neuroscience (3119)
Neurotech (1)
NextGen: Class of 2026 (6582)
Non-profit (4500)
Now hiring (53)
Obesity (692)
Opinion (326)
Ovarian cancer (169)
Pain (216)
Pancreatic cancer (236)
Parkinson's disease (299)
Partnered (37)
Patents (518)
Patient recruitment (499)
Peanut (60)
People (59677)
Pharmaceutical (55)
Pharmacy benefit managers (33)
Phase 1 (21579)
Phase 2 (30548)
Phase 3 (23554)
Pipeline (5367)
Policy (337)
Postmarket research (2809)
Preclinical (9215)
Press Release (68)
Prostate cancer (252)
Psychedelics (58)
Radiopharmaceuticals (293)
Rare diseases (932)
Real estate (6168)
Recruiting (74)
Regulatory (26100)
Reports (51)
Research institute (2561)
Resumes & cover letters (478)
Rett syndrome (28)
RNA editing (21)
RSV (81)
Schizophrenia (161)
Series A (256)
Series B (203)
Service/supplier (13)
Sickle cell disease (101)
Special edition (27)
Spinal muscular atrophy (168)
Sponsored (46)
Startups (3783)
State (2)
Stomach cancer (20)
Supply chain (113)
Tariffs (101)
The Weekly (118)
Vaccines (1161)
Venture capital (100)
Weight loss (477)
Women's health (88)
Worklife (22)
Date
Today (20)
Last 7 days (629)
Last 30 days (2125)
Last 365 days (31455)
2026 (3642)
2025 (31849)
2024 (36229)
2023 (40920)
2022 (51979)
2021 (56248)
2020 (54306)
2019 (46584)
2018 (35336)
2017 (34126)
2016 (33868)
2015 (38939)
2014 (33749)
2013 (29175)
2012 (29271)
2011 (29708)
2010 (27800)
Location
Africa (970)
Alabama (88)
Alaska (6)
Arizona (290)
Arkansas (12)
Asia (43213)
Australia (7410)
California (11485)
Canada (3194)
China (1133)
Colorado (471)
Connecticut (497)
Delaware (348)
Europe (101573)
Florida (1703)
Georgia (364)
Hawaii (4)
Idaho (56)
Illinois (901)
India (69)
Indiana (530)
Iowa (23)
Japan (444)
Kansas (124)
Kentucky (37)
Louisiana (27)
Maine (80)
Maryland (1443)
Massachusetts (8371)
Michigan (337)
Minnesota (650)
Mississippi (6)
Missouri (132)
Montana (27)
Nebraska (26)
Nevada (124)
New Hampshire (81)
New Jersey (3083)
New Mexico (31)
New York (3023)
North Carolina (1553)
North Dakota (10)
Northern California (5603)
Ohio (338)
Oklahoma (23)
Oregon (43)
Pennsylvania (2261)
Puerto Rico (21)
Rhode Island (46)
South America (1352)
South Carolina (65)
South Dakota (1)
Southern California (4477)
Tennessee (173)
Texas (1770)
United States (40957)
Utah (334)
Vermont (1)
Virginia (277)
Washington D.C. (83)
Washington State (945)
West Virginia (4)
Wisconsin (124)
Wyoming (2)
739,248 Results for "pharmexa a s formerly m and e biotech a s".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Insights
Uptick in Dealmaking, Chinese Partnerships Drive Biotech’s Comeback
Biotech’s slump may finally be over in 2026. In interviews with
BioSpace
, Zymeworks’ CEO Ken Galbraith and Zai Lab’s President and COO Josh Smiley explain what’s fueling the comeback.
December 17, 2025
·
3 min read
·
Jennifer Smith-Parker
Insights
Biotech’s Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
January 29, 2026
·
3 min read
·
Jennifer Smith-Parker
Insights
Biotech’s New Cycle, JPM Deal Hype and Where Alpha Still Hides
In this episode of Denatured, Jennifer C. Smith-Parker speaks with RTW’s Rod Wong and Stephanie Sirota how shifting JPM deal timing masks record M&A potential; why oncology, obesity, psychedelics, and neuroscience are attracting fresh capital; and how “alpha stacking” shapes their investment edge in an age of chronic uncertainty. They cover topics discussed in RTW’s new book, “Innovation is the Best Medicine.”
January 29, 2026
·
1 min read
·
Jennifer Smith-Parker
Mergers & acquisitions
6 Biotechs That Could Be Big Pharma’s Next M&A Target
Metsera showed the biopharma world that M&A is back. Who could be next?
December 17, 2025
·
8 min read
·
Annalee Armstrong
Regulatory
6 Biotechs With a Shot at the FDA’s Platform Technology Designation
After revoking Sarepta’s award in July and awarding one to Krystal last month, the FDA’s platform technology designation program appears to be back on track. These six biotechs could be on the regulator’s radar.
November 21, 2025
·
9 min read
·
Tristan Manalac
Legal
CytoDyn’s Former CEO Gets Jail Time, $5.3M+ Fine for Securities Fraud
Nader Pourhassan, who led CytoDyn for nearly 10 years, was convicted in December 2024 of misleading investors regarding the biotech’s investigational COVID-19 and HIV drug, which artificially inflated its share price.
January 27, 2026
·
2 min read
·
Tristan Manalac
Opinion
Trump Must Make Biotech Innovation a National Priority
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
January 14, 2026
·
7 min read
·
Cyriac Roeding
Podcast
Lilly’s Triple Triumph, Prasad’s COVID Error, J&J’s Surprise Voucher, M&A Targets
Eli Lilly’s retatrutide exceeds expectations in Phase III, capping off a sparkling 2025 for the obesity titan; an internal FDA safety review finds no confirmed pediatric deaths caused by COVID-19 vaccines, and Commissioner Marty Makary says no black box warning will be attached to the shots; and BioSpace looks at six biotechs that could be pharma’s next buy.
December 17, 2025
·
2 min read
·
Heather McKenzie
Editorial
All the Ways Moderna’s Flu Vaccine Rejection Letter Shocked Us
The FDA issued a rare Refusal-to-File letter to Moderna over its mRNA-based influenza vaccine application, in an unusual move that sent the biotech’s shares tumbling.
February 11, 2026
·
4 min read
·
Dan Samorodnitsky
Alzheimer’s disease
In Novo’s GLP-1 Failure, Alzheimer’s Space Spies a Combination Opportunity
Despite the definitive failure of Novo Nordisk’s semaglutide in Alzheimer’s, biotech executives, analysts and other industry experts see potential in more testing of GLP-1s for the neurodegenerative disease, particularly in a combination approach.
January 2, 2026
·
5 min read
·
Annalee Armstrong
1 of 73,925
Next